Skip to main content

ABEO

Stock
Health Care
Biotechnology

Performance overview

ABEO Price
Price Chart

Forward-looking statistics

Beta
0.57
Risk
63.55%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Company info

SectorHealth Care
IndustryBiotechnology
Employees91
Market cap$175.9M

Fundamentals

Enterprise value$230.4M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity57.92

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.63
Dividend per share
Revenue per share$0.00
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$11M
Put-call ratio

Macro factor sensitivity

Growth+4.3
Credit+3.8
Liquidity-0.7
Inflation+2.8
Commodities+0.7
Interest Rates+0.2

Valuation

Dividend yield0.00%
PEG Ratio-3.98
Price to sales
P/E Ratio-3.98
Enterprise Value to Revenue
Price to book6.96

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend dayMarch 31, 2000

News

Abeona Surges After FDA Clears First Gene Therapy For Severe Genetic Skin Disease

Abeona Therapeutics Inc.'s  ABEO stock traded higher on Wednesday.

Benzinga (April 30, 2025)
Here's Why Abeona Therapeutics (ABEO) Looks Ripe for Bottom Fishing

Abeona Therapeutics (ABEO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Zacks Investment Research (January 25, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free